Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PAT-1251
GB2064 · 1 trial · 1 indication
Incidence and severity of adverse events as reported by investigators
| Arm | Type | Description |
|---|---|---|
| GB2064 | EXPERIMENTAL | GB2064 will be administered orally as 4 x 250 mg tablets twice a day. |
| Name | Type | Description |
|---|---|---|
| GB2064 | DRUG | GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day |
Inclusion Criteria: Participants must satisfy all of the following criteria at the Screening visit: 1. Adult male or female participants ≥ 18 years of age at enrolment: 1. Female participants may be of non-childbearing potential defined as permanently sterile or postmenopausal, or female parti...
GB2064 is an investigational small molecule being studied for the treatment of myelofibrosis, a bone marrow cancer. It is in Phase 2 clinical development and is not approved for any indication. Development is led by Damora Therapeutics, Inc.
GB2064 targets LOXL2, an enzyme. By inhibiting LOXL2, the drug is designed to act on the lysyl oxidase family of enzymes, which are involved in remodeling of the bone marrow environment. This mechanism is being explored in the myelofibrosis setting.
GB2064 is being developed by Damora Therapeutics, Inc., which trades under the ticker DMRA. The company is running the clinical program for the asset in myelofibrosis.
GB2064 is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA or any other regulatory authority. The ongoing study is active but no longer recruiting participants.
GB2064 is being evaluated in one clinical trial, NCT04679870, titled a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral GB2064 in participants with myelofibrosis. The Phase 2 trial is active and not recruiting, with 21 participants enrolled across the United States, Australia, Germany, and Italy.
Yes, GB2064 is also known as PAT-1251. Both names refer to the same investigational LOXL2 inhibitor being developed by Damora Therapeutics, Inc. for myelofibrosis, so readers searching for either name are looking at the same drug asset.